Dacarbazine
Information
- Drug Name
- Dacarbazine
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| MITF amplification does not predict chemosensitivi... | MITF | MITF AMP | Resitance or Non-Reponse | true | MMMP | detail |
| mRNA expression of MGMT, MLH1 and MSH2 in the peri... | MGMT | MGMT EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| mRNA expression of MGMT, MLH1 and MSH2 in the peri... | MLH1 | MLH1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| mRNA expression of MGMT, MLH1 and MSH2 in the peri... | PMS1 | PMS1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| The genetic variant rs2303428 (MSH2) might serve a... | MSH2 |
MSH2 rs2303428
MSH2 c.2006-6T>C ( ENST00000543555.6, ENST00000233146.7, ENST00000406134.5, ENST00000645506.1, ENST00000713854.1, ENST00000713919.1 ) MSH2 rs2303428 |
Sensitivity | true | MMMP | detail |
| Phase III RCT. Setting: advanced disease. No overa... | BCL2 | BCL2 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| In a phase II trial (n=72), anti-CTLA4 antibody ip... | CTLA4 | CTLA4 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Bcl-2 antisense therapy chemosensitizes human mela... | BCL2 | BCL2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Rac1/JNK activation is critical for cell cycle arr... | HDAC9 | HDAC9 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| The consistent synergy seen for imexon and alkylat... | ROS1 | ROS1 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| Strong synergistic proapoptotic effect of the Bcl-... | BCL2 | BCL2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Adjuvant setting; IFN alone increased survival | IFNAR1 | IFNAR1 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Combination of tamoxifen with CDDP was highly syne... | ESR1 | ESR1 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| HER3 silencing increases DTIC activity | ERBB3 | ERBB3 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Mcl-1 antisense therapy chemosensitizes human mela... | MCL1 | MCL1 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Dacarbazine causes transcriptional upregulation of... | VEGFA | VEGFA EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| The 93 patients were treated with DTIC or TMZ. Leu... | MGMT | MGMT EXPRESSION | toxicity decrease | true | MMMP | detail |
| The genetic variant rs2303428 (MSH2) might serve a... | MSH2 |
MSH2 rs2303428
MSH2 c.2006-6T>C ( ENST00000543555.6, ENST00000233146.7, ENST00000406134.5, ENST00000645506.1, ENST00000713854.1, ENST00000713919.1 ) MSH2 rs2303428 |
toxicity increased | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03907488 | Active, not recruiting | Phase 3 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | August 29, 2019 | April 1, 2025 |
| NCT00600496 | Active, not recruiting | Phase 1 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | December 14, 2007 | December 31, 2024 |
| NCT03070392 | Active, not recruiting | Phase 2 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | October 16, 2017 | June 2025 |
| NCT03407144 | Active, not recruiting | Phase 2 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | April 9, 2018 | February 13, 2027 |
| NCT03331341 | Active, not recruiting | Phase 2 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | January 9, 2019 | July 1, 2029 |
| NCT03712202 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | November 28, 2018 | September 23, 2024 |
| NCT03004833 | Active, not recruiting | Phase 2 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | February 21, 2017 | December 2023 |
| NCT03233347 | Active, not recruiting | Phase 2 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | October 13, 2017 | July 8, 2025 |
| NCT03646123 | Active, not recruiting | Phase 2 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | January 28, 2019 | June 7, 2026 |
| NCT02979522 | Active, not recruiting | Phase 1/Phase 2 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | September 6, 2017 | September 24, 2029 |
| NCT03023124 | Active, not recruiting | Phase 2 | Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor | March 4, 2018 | December 2024 |
| NCT02661503 | Active, not recruiting | Phase 3 | HD21 for Advanced Stages | July 2016 | September 2025 |
| NCT01868451 | Active, not recruiting | N/A | Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | May 2013 | May 2026 |
| NCT01771107 | Active, not recruiting | Phase 1/Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | March 7, 2013 | February 28, 2025 |
| NCT05269355 | Active, not recruiting | Phase 2/Phase 3 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | May 23, 2022 | June 30, 2024 |
| NCT03016819 | Active, not recruiting | Phase 3 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | August 15, 2017 | June 2025 |
| NCT03226249 | Active, not recruiting | Phase 2 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | November 9, 2017 | October 2024 |
| NCT03517137 | Active, not recruiting | Phase 2 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | August 1, 2019 | November 16, 2026 |
| NCT01712490 | Active, not recruiting | Phase 3 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | November 9, 2012 | January 13, 2026 |
| NCT05008224 | Active, not recruiting | Phase 2 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | October 7, 2021 | May 22, 2024 |
| NCT03159897 | Active, not recruiting | Phase 3 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | August 1, 2017 | May 2024 |
| NCT00246012 | Completed | Phase 1/Phase 2 | A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma | May 2005 | February 2009 |
| NCT00257205 | Completed | Phase 3 | CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | March 2006 | August 2010 |
| NCT00308607 | Completed | Phase 2 | Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma | August 2005 | April 2009 |
| NCT00324155 | Completed | Phase 3 | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma | August 2006 | October 2013 |
| NCT00369681 | Completed | Phase 2 | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | May 2006 | October 2014 |
| NCT00412581 | Completed | Phase 1 | Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma | September 2005 | March 2008 |
| NCT00416832 | Completed | Phase 2 | Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma | November 2002 | December 2005 |
| NCT00433459 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma | January 2007 | January 2013 |
| NCT00498979 | Completed | Phase 1 | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | May 2007 | January 2012 |
| NCT00516802 | Completed | Phase 1 | A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine | January 2007 | January 2009 |
| NCT00533702 | Completed | Phase 2 | A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma | November 2007 | May 2011 |
| NCT00654732 | Completed | Phase 2 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | March 19, 2008 | September 5, 2018 |
| NCT00678327 | Completed | Phase 3 | Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma | August 29, 2008 | May 1, 2024 |
| NCT00796991 | Completed | Phase 1 | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | February 2009 | October 2012 |
| NCT00802880 | Completed | Phase 2 | Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma | March 2009 | January 2015 |
| NCT00822120 | Completed | Phase 2 | S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma | July 2009 | June 30, 2022 |
| NCT00864253 | Completed | Phase 3 | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | April 23, 2009 | February 12, 2014 |
| NCT00936221 | Completed | Phase 2 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | July 2009 | November 2014 |
| NCT01006980 | Completed | Phase 3 | A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | January 2010 | July 2015 |
| NCT01060904 | Completed | Phase 1 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | January 2010 | September 2012 |
| NCT01100528 | Completed | Phase 2 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | November 11, 2009 | December 14, 2017 |
| NCT01132807 | Completed | Phase 2 | Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | May 2010 | January 2018 |
| NCT01133977 | Completed | Phase 1/Phase 2 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | April 2010 | November 2014 |
| NCT01143402 | Completed | Phase 2 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | June 2010 | May 2016 |
| NCT01152788 | Completed | Phase 2 | Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | August 5, 2010 | February 13, 2015 |
| NCT01164007 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma | June 30, 2006 | May 31, 2012 |
| NCT01251107 | Completed | Phase 3 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | March 2000 | November 2009 |
| NCT01343277 | Completed | Phase 3 | A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | June 2011 | April 2016 |
| NCT01359956 | Completed | Phase 3 | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma | April 2002 | February 2011 |
| NCT01404936 | Completed | Phase 2 | Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | July 1996 | December 2011 |
| NCT01551459 | Completed | Phase 2 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma | October 2010 | November 2017 |
| NCT01569204 | Completed | Phase 2 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | October 2012 | December 2017 |
| NCT01681212 | Completed | Phase 2 | Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma | October 2012 | May 2014 |
| NCT01692678 | Completed | Phase 3 | A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma | August 7, 2012 | October 11, 2016 |
| NCT01693068 | Completed | Phase 2 | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | December 5, 2012 | October 24, 2016 |
| NCT01704287 | Completed | Phase 2 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | November 20, 2012 | January 31, 2019 |
| NCT01716806 | Completed | Phase 2 | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | October 31, 2012 | September 12, 2023 |
| NCT00002561 | Completed | Phase 3 | Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease | January 25, 1994 | January 6, 2012 |
| NCT00002669 | Completed | Phase 2 | Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | June 1995 | |
| NCT00002791 | Completed | Phase 2 | Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma | February 1997 | November 2013 |
| NCT00002802 | Completed | Phase 3 | Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma | July 1990 | September 2003 |
| NCT00002882 | Completed | Phase 3 | Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma | November 1995 | April 2006 |
| NCT00003027 | Completed | Phase 3 | Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma | November 13, 1997 | |
| NCT00003389 | Completed | Phase 3 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | June 17, 1999 | May 2016 |
| NCT00003421 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease | June 1998 | November 2005 |
| NCT00003647 | Completed | Phase 3 | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma | July 1998 | September 2002 |
| NCT00004010 | Completed | Phase 2 | Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | October 1999 | June 2008 |
| NCT00004141 | Completed | Phase 2 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma | August 1998 | April 2006 |
| NCT00006237 | Completed | Phase 3 | S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma | August 2000 | July 2012 |
| NCT00016263 | Completed | Phase 3 | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma | July 2000 | December 2004 |
| NCT00017225 | Completed | Phase 2 | Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | May 1997 | February 2002 |
| NCT00023738 | Completed | Phase 1/Phase 2 | Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma | August 2001 | October 2003 |
| NCT00049595 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma | August 2002 | |
| NCT00070642 | Completed | Phase 2 | CPG 7909 Injection in Melanoma | December 2003 | December 2005 |
| NCT00072124 | Completed | Phase 3 | Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma | September 2003 | May 2005 |
| NCT00091572 | Completed | Phase 3 | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) | October 20, 2004 | December 31, 2007 |
| NCT00110994 | Completed | Phase 2 | Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | April 2005 | March 2008 |
| NCT00000626 | Completed | Phase 2 | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | February 1999 | |
| NCT01721746 | Completed | Phase 3 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | December 21, 2012 | December 29, 2020 |
| NCT01721772 | Completed | Phase 3 | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | January 18, 2013 | May 14, 2021 |
| NCT01763164 | Completed | Phase 3 | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | July 12, 2013 | June 4, 2019 |
| NCT01835145 | Completed | Phase 2 | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | July 31, 2013 | November 1, 2019 |
| NCT01974752 | Completed | Phase 3 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) | April 2014 | October 2016 |
| NCT02181738 | Completed | Phase 2 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | August 12, 2014 | December 27, 2022 |
| NCT02292979 | Completed | Phase 2 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | March 2015 | June 2, 2022 |
| NCT02505269 | Completed | Phase 2 | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | August 7, 2015 | June 2019 |
| NCT02545075 | Completed | Phase 3 | A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | October 31, 2015 | April 19, 2019 |
| NCT03761095 | Completed | Phase 1 | A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | March 13, 2019 | February 5, 2024 |
| NCT06201507 | Enrolling by invitation | Phase 2 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | October 1, 2022 | December 31, 2025 |
| NCT04733183 | Recruiting | Phase 2 | Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma | August 28, 2020 | December 2024 |
| NCT04727242 | Recruiting | Phase 2 | CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma | January 28, 2021 | January 2025 |
| NCT04685616 | Recruiting | Phase 3 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | April 14, 2022 | September 2032 |
| NCT06346067 | Recruiting | Phase 3 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | April 29, 2024 | December 2028 |
| NCT06377566 | Recruiting | Phase 2 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | April 17, 2024 | April 2027 |
| NCT04638790 | Recruiting | Phase 3 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | February 1, 2020 | December 31, 2026 |
| NCT04067037 | Recruiting | Phase 2 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | August 26, 2019 | December 31, 2024 |
| NCT04221035 | Recruiting | Phase 3 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | November 5, 2019 | November 2032 |
| NCT05987332 | Recruiting | Phase 2/Phase 3 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | October 31, 2023 | January 15, 2028 |
| NCT03033914 | Recruiting | Phase 1/Phase 2 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | January 25, 2017 | January 2026 |
| NCT02797717 | Recruiting | N/A | Treatment for Classical Hodgkin Lymphoma in Children and Adolescents | November 2015 | December 2027 |
| NCT05922904 | Recruiting | Phase 2 | PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | December 14, 2023 | October 30, 2025 |
| NCT06164275 | Recruiting | Phase 2 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | February 6, 2024 | December 31, 2031 |
| NCT05675410 | Recruiting | Phase 3 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | May 11, 2023 | April 28, 2031 |
| NCT03277924 | Recruiting | Phase 1/Phase 2 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas | May 31, 2017 | June 30, 2025 |
| NCT05404945 | Recruiting | Phase 2 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | July 26, 2022 | October 3, 2027 |
| NCT02190838 | Terminated | Phase 2 | Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma | April 2014 | December 31, 2018 |
| NCT01390584 | Terminated | Phase 2 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | May 24, 2013 | May 18, 2018 |
| NCT01280565 | Terminated | Phase 3 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | January 2011 | August 2019 |
| NCT00920153 | Terminated | Phase 3 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | May 2008 | March 2016 |
| NCT00849875 | Terminated | Phase 2 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | May 26, 2009 | November 17, 2014 |
| NCT00615160 | Terminated | Phase 1/Phase 2 | PTK/ZK in Disseminated Malignant Melanoma | December 2006 | September 2008 |
| NCT00496223 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of Sunitinib and Dacarbazine | September 2006 | June 2007 |
| NCT00089544 | Terminated | Phase 2 | Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall | June 17, 2004 | November 5, 2013 |
| NCT00033644 | Terminated | Phase 2 | Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus | March 2002 | |
| NCT01705392 | Terminated | Phase 2 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | January 2013 | February 20, 2017 |
| NCT01692691 | Terminated | Phase 2 | Dacarbazine and Carmustine in Metastatic Melanoma | August 2012 | October 2014 |
| NCT00005090 | Terminated | Phase 3 | S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease | April 2000 | May 2005 |
| NCT01542255 | Terminated | Phase 2 | Metronomic Therapy in Patients With Metastatic Melanoma | June 2010 | January 2013 |
| NCT01476410 | Unknown status | Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | November 2011 | May 2021 |
| NCT00070343 | Unknown status | N/A | Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 | August 2003 | |
| NCT00006200 | Unknown status | Phase 2 | Thalidomide and Dacarbazine for Metastatic Melanoma | ||
| NCT00526318 | Unknown status | N/A | Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | January 2007 | |
| NCT00410631 | Unknown status | Phase 3 | Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | October 2004 | |
| NCT01468740 | Unknown status | Phase 2 | Prospective Study on HIV-related Hodgkin Lymphoma | March 2004 | July 2012 |
| NCT00025064 | Unknown status | Phase 2 | Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma | January 2000 | |
| NCT00041210 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma | October 2001 | |
| NCT03527628 | Unknown status | Phase 2 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | January 1, 2018 | January 15, 2022 |
| NCT00416377 | Unknown status | N/A | Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma |